Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and ...

A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the ...

GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on ...

Company awarded patents in the U.S. and Hong Kong "We are building a robust portfolio of drug candidates to sensitize cancer to radiation therapy and to activate the immune system to target irradiated ...

Researchers from Northeast Normal University in Changchun demonstrated that compound AW-01178 reversed the abnormal regulation of E-cadherin, a protein that plays a role in the epithelial-mesenchymal ...

Writing in the Journal of Medicinal Chemistry, researchers from Shenzhen University Medical School and collaborating institutions report the design, synthesis and biological evaluation of a series of ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis ...

PHILADELPHIA -- (March 27, 2018) -- Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of ...

Scientists from the Icahn School of Medicine at Mount Sinai (MSSM) have published a study that describes the biological mechanism used by a family of proteins called histone deacetylases to activate ...